# US 2026/0077054 A1 · Combinations of anti-gip antibodies and incretins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077054 A1
- Document ID: US20260077054A1
- Status: Published application
- Kind: A1
- Application number: 19/333,060
- Filed: 2025-09-18
- Published: 2026-03-19
- Earliest claimed: 2024-09-18
- Assignees: Helicore Biopharma, Inc.
- Applicants: Helicore Biopharma, Inc.
- Inventors: James Patterson; Jing Liang; Paul Kierstead
- Web page: https://patentgrep.com/patent/US20260077054A1

## CPC

- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6847: {the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
- A61P 3/04: Anorexiants; Antiobesity agents
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided for herein are anti-GIP antibodies, or antigen-binding fragments thereof. Conjugates of the anti-GIP antibodies, or antigen-binding fragments thereof, to biologically active peptides are also provided. Pharmaceutical compositions of the, anti-GIP antibodies, or antigen-binding fragments thereof, biologically active peptides, combinations thereof, or conjugates thereof are also provided. Methods of using the embodiments and compositions provided for herein are also provided.

## Claims

### Claim 1

A conjugate, comprising an anti-glucose-dependent insulinotropic polypeptide (GIP) antibody, or an antigen-binding fragment thereof, conjugated to a biologically active peptide, wherein the biologically active peptide comprises a glucagon like peptide 1 receptor (GLP-1R) agonist.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the anti-GIP antibody, or antigen-binding fragment thereof comprises a heavy chain (HC) comprising a variable heavy chain region (VH) and a light chain (LC) comprising a variable light chain region (VL), wherein the VH comprises a heavy chain complementarity domain 1 (HCDR1), a HCDR2, and a HCDR3 comprising amino acid sequences selected from:
a. SEQ ID NO: 15, SEQ ID NO: 26, and SEQ ID NO: 17,
b. SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3,
c. SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, or
and wherein the VL comprises a light chain complementarity domain 1 (LCDR1), a LCDR2, and a LCDR3 comprising amino acid sequences selected from:
d. SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 19,
e. SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6,
f. SEQ ID NO: 18, SEQ ID NO: 5, and SEQ ID NO: 19,
g. SEQ ID NO: 27, SEQ ID NO: 31, and SEQ ID NO: 19, or
h. SEQ ID NO: 27, SEQ ID NO: 34, and SEQ ID NO: 19.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein the VH comprises an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 29, SEQ ID NO: 13, SEQ ID NO: 24, SEQ ID NO: 32, or SEQ ID NO: 35.

### Claim 4 (depends on 2)

The conjugate of claim 2, wherein the VL comprises an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NO: 30, SEQ ID NO: 14, SEQ ID NO: 25, SEQ ID NO: 33, or SEQ ID NO: 36.

### Claim 5 (depends on 2)

The conjugate of claim 2, wherein the VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 29 and the VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 30, wherein the VH comprises a HCDR1 comprising an amino acid sequence of SEQ ID NO: 15, a HCDR2 comprising an amino acid sequence of SEQ ID NO: 26, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 17, and the VL comprises a LCDR1 comprising an amino acid sequence of SEQ ID NO: 27, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 28, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 19.

### Claim 6 (depends on 2)

The conjugate of claim 2, wherein the HC comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 37 and the LC comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 144.

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein the biologically active peptide is conjugated to the anti-GIP antibody, or antigen-binding fragment thereof, through the substituted cysteine residue on the anti-GIP antibody.

### Claim 8 (depends on 1)

The conjugate of claim 1, wherein the GLP-1R agonist is liraglutide, albiglutide, taspoglutide, semaglutide, LY2428757, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 145, or SEQ ID NO: 146, or a peptide that is 95% identical thereto.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The conjugate of claim 1, wherein the biologically active peptide is conjugated to the anti-GIP antibody, or antigen-binding fragment thereof, within a CL, CH1, CH2, or CH3 region of the anti-GIP antibody, or antigen-binding fragment thereof.

### Claim 11 (depends on 1)

The conjugate of claim 1, wherein the anti-GIP antibody, or antigen-binding fragment thereof, comprises an Fc region.

### Claim 12 (depends on 11)

The conjugate of claim 11, wherein the Fc region is an IgG Fc.

### Claim at position 13

-14. (canceled)

### Claim 15 (depends on 12)

The conjugate of claim 12, wherein the IgG Fc is an IgG1 Fc, and wherein the IgG1 Fc comprises one or more substitutions of a canonical amino acid to a cysteine at position 70, 89, 109, 111, 118, 124, 140, 152, 239, 265, 272, 290, 300, 345, 359, 390, or 442.

### Claim 16 (depends on 15)

The conjugate of claim 15, wherein the substitution of a canonical amino acid to a cysteine comprises a D70C, E89C, V109C, A111C, A118C, S124C, A140C, E152C, S239C, V265C, E272C, K290C, Y300C, E345C, T359C, N390C, or S442C mutation.

### Claim 17 (depends on 10)

The conjugate of claim 10, wherein the CL domain comprises one or more substitutions of a canonical amino acid to a cysteine at position 149, 205, or any combination thereof.

### Claim 18 (depends on 17)

The conjugate of claim 17, wherein the substitution of a canonical amino acid to a cysteine comprises a K149C or V205C substitution.

### Claim 19

(canceled)

### Claim 20

A conjugate comprising an anti-glucose-dependent insulinotropic polypeptide (GIP) antibody, or an antigen-binding fragment thereof, conjugated to a biologically active peptide,
wherein the biologically active peptide is conjugated to the anti-GIP antibody, or antigen-binding fragment thereof, through one or more substitutions of a canonical amino acid to a cysteine,
wherein the one or more substitution of a canonical amino acid to a cysteine comprises an E272C, K290C, or S442C mutation in a heavy chain of the antibody, and/or a K149C or V205C substitution in a light chain of the antibody, and
wherein the biologically active peptide comprises a glucagon like peptide 1 receptor (GLP-1R) agonist.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the conjugate of claim 1.

### Claim at position 22

-40. (canceled)

### Claim 41 (depends on 1)

A method of treating a disease or disorder in a patient in need thereof, the method comprising administering the conjugate of claim 1, or a pharmaceutical composition comprising the same, to the patient, thereby treating the disease or disorder.

### Claim at position 24

-43. (canceled)

### Claim 44 (depends on 1)

A method of treating a disease or disorder in a diabetic patient in need thereof, the method comprising administering to the diabetic patient the conjugate of claim 1, or a pharmaceutical composition comprising the same, to the patient, thereby treating the disease or disorder,
wherein the disease or disorder is selected from coronary heart disease, lipodystrophy, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, fatty liver disease, hyperphagia, metabolic syndrome, hyperthyroidism, ischemic heart disease, hypertension, stable angina pectoris, unstable angina, acute coronary syndrome, ST elevation myocardial infarction, non-ST elevation myocardial infarction, or any combination thereof.

### Claim at position 26

-47. (canceled)

### Claim 48 (depends on 1)

A method for blunting or reducing cravings in a subject in need thereof, the method comprising administering to the patient the conjugate of claim 1, or a pharmaceutical composition comprising the same, to the patient, thereby blunting or reducing the cravings.

### Claim 49

(canceled)
